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Background: Ribavirin is an anti-viral drug; however, recent data suggest that it may also be effective in cancer
therapy. This study investigated the effect of ribavirin alone or in combination with IFN-α on biological processes:
proliferation, apoptosis, and migration of murine (Renca) and human renal carcinoma (RCC) cells (786–0) in vitro.
Methods: Renca and 786–0 cells were treated with IFN-α, ribavirin, or a combination of IFN-α and ribavirin at
varying concentrations. Cell proliferation was evaluated using CCK-8 assay. Induction of apoptosis and distribution
of cell cycle were determined by flow cytometry. The migratory capacity of cells was quantified using a transwell
migration assay. The toxic effect of these drugs was examined using MTT assay in HEK-293 cells. ELISA was used to
measure IL-10 and TGF-β content in the culture supernatants.
Results: Our results showed that both ribavirin alone and in combination with IFN-α could significantly inhibit the
cell proliferation and arrest the cell cycle progress at the G2/M phase. These treatments also inhibited cell migration
and IL-10 production, in a concentration-dependent manner, in 786–0 and Renca cells. Moreover, they significantly
induced apoptosis of RCC cells and increased TGF-β production in concentration-dependent manner. No significant
toxic effect was observed in HEK-293 cells. We also found that the effect of combined treatment was more pronounced
than that of ribavirin or IFN-α alone. However, the combined effect of the two drugs was not synergistic.
Conclusion: Our findings suggest that ribavirin can negatively affect biological processes of RCC cells. This agent
might become a new candidate for the treatment of RCC in the clinical setting.
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Renal cell carcinoma (RCC) is one of the cancers most
resistant to currently available chemotherapy, radiother-
apy, and immunotherapy. Although nephrectomy and
nephron-sparing surgery (NSS) are still the mainstream
therapies in RCC, satisfactory outcomes are only achieved
in patients with localized RCC. A Canadian study has
demonstrated that at the time of first diagnosis, 25% of pa-
tients with RCC are diagnosed with locally advanced RCC* Correspondence: zhongjieqiao@hotmail.com; 504587957@qq.com
†Equal contributors
1Department of Urology, The Affiliated Tumor Hospital, Harbin Medical
University, No. 150 Haping Road, Harbin city, Heilongjiang Province 150081,
China
2Department of Urology, The First Affiliated Hospital, Harbin Medical
University, No. 31 Youzheng Street, Harbin city, Heilongjiang Province
150080, China
© 2014 Teng et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.with lymph node or local organ involvement, and 30%
would present with metastasis [1]. Two decades ago, cyto-
kine therapy, such as IL-2 or interferon alone or adminis-
tered together, were typically used in the initial RCC
therapy. The patients with the advanced or metastatic
RCC would need a combination of surgery and immuno-
therapy. Unfortunately, only a small proportion of such
patients show significant and durable response to im-
munotherapy. Since the advent of targeted therapy, tyro-
sine kinase inhibitors, such as sorafenib and sunitinib,
have attracted worldwide attention, bringing new hope to
RCC patients. However, target therapy rarely gives a
complete response in patients with localized or metastatic
RCC. In addition, because of the high cost and severe side
effects of such interventions, these drugs have not been
widely used in China.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mide) is a well-known anti-virus drug, widely used in the
treatment of various viral infections, especially hepatitis-C
infections [2,3]. This drug can markedly improve out-
come for patients with hepatitis C; nevertheless, its precise
mode of action has remained elusive. Some researchers
have focused on potential immunomodulatory properties
of ribavirin. A recently published study has demonstrated
that ribavirin can inhibit the function of HCV-specific
regulatory T cells and reverse the suppression of T effector
cells [4]. The study suggests that ribavirin might exert a
similar immunomodulatory effect in anti-cancer therapies.
Some studies have shown that ribavirin can inhibit the ac-
tivity of oncogenic eukaryotic translation-initiation factor
eIF4E [5-8]. All these data have triggered our renewed
interest in the potential effect of ribavirin on cancer cells.
Interferon-α (IFN-α) has shown anti-tumor activity in a
variety of solid tumors and has been approved for RCC
treatment. However, the available evidence demonstrates
that IFN-α only produces modest benefits in unselected
patients; randomized clinical trials show only a small sur-
vival benefit [9,10]. This limited efficacy of IFN-α treat-
ment has narrowed its application as a single agent in
patients with RCC. Some investigators have even con-
cluded that subcutaneous IFN-α should not be recom-
mended for patients with metastatic RCC. However, it is
worth considering combining IFN-α with other agents.
This approach might enhance the anti-tumor effect of
IFN-α in RCC. For example, combined ribavirin and
IFN-α treatment might have a synergistic effect in the
management of RCC. This study investigated the inhibi-
tory effect of ribavirin and IFN-α on human and mouse
RCC cell lines in vitro.
Results
The effect of IFN-α, ribavirin, or a combination of IFN-α
and ribavirin on the proliferation of renca and 786–0 cells
Renca and 786–0 cells were treated with IFN-α, ribavi-
rin, or a combination of IFN-α and ribavirin for 72 h.
We observed significant decrease in OD values with
increasing concentration of IFN-α (0, 20, 100, 500,
1000 IU/ml) or ribavirin (0, 100, 300, 500, 1000 μM) in
both cell lines (p < 0.05). These data demonstrate that
the cell proliferation can be suppressed by IFN-α or riba-
virin in a concentration-dependent manner. To investigate
whether combined treatment can have a synergistic effect
on the proliferation of these cells, the cell cultures were
incubated with IFN-α and ribavirin at different concen-
trations (IFN-α at 500 or 1000 IU/ml and ribavirin at
500 or 1000 μM). We observed that, in comparison with
ribavirin-only treatment, combined treatment signifi-
cantly inhibited the proliferation of Renca and 786–0
cells in a concentration-dependent manner (p < 0.05).
However, for both cell lines, the combined treatmentwith 500 IU/ml of IFN-α and 500 μM ribavirin produced
OD values higher than after incubation with 1000 IU/ml
of IFN-α. In addition, the OD values reached 0.404 and
0.345 at the concentrations of 1000 IU/ml of IFN-α and
1000 μM ribavirin in Renca and 786–0 cells, respectively.
The results are shown in Figure 1A and B. The results
demonstrate that the combination of IFN-α and ribavirin
has stronger inhibitory effect on RCC cell growth than
incubation with ribavirin alone. However, the confi-
dence interval (CI) values showed an additive inhibitory
effect when RCC cell lines were treated with IFN-α and
ribavirin.
The effect of IFN-α alone, ribavirin alone, or a
combination of IFN-α and ribavirin on apoptosis of
human and murine RCC cells
Our results showed that IFN-α or ribavirin alone can in-
duce apoptosis of RCC cells. However, the effect at lower
concentrations of those agents was slight; only 1–2%
apoptosis was observed in the cells treated with 20 IU/ml
IFN-α or 300 μM ribavirin. With higher concentrations of
IFN-α or ribavirin, we observed significantly increasing
apoptosis rate, to a maximum of 60–70% at 500 IU/ml of
IFN-α or 1000 μM ribavirin (Figure 2A and B). Thus, the
effect of these agents on apoptosis was concentration-
dependent. Interestingly, higher percentages of apoptotic
cells (80–92%) were observed in RCC cells treated with a
combination of IFN-α and ribavirin at high concentration
levels (Figure 2C). CompuSyn analysis showed that com-
bined treatment with IFN-α and ribavirin had an additive
effect on apoptosis in RCC cells.
The effect of ribavirin and IFN-α on 786–0 cell cycle
Apart from the inhibition of proliferation and induction
of apoptosis in RCC cells, we also investigated the effect
of ribavirin and IFN-α on 786–0 cell cycle. Our results,
shown in Figure 3A and B, demonstrate that the per-
centages of 786–0 cells in the G0/G1 and S phase were
similar in treated and untreated samples. With increasing
concentration, however, the percentage of 786–0 cells in
the G2/M phase decreased significantly, from 25.52% to
13.95%. The percentage of cells in the G2/M phase was
lowest (13.95%) after treatment with 500 μM of ribavirin
and 500 IU/ml of IFN-α. These results suggest that riba-
virin and IFN-α induce the cell cycle arrest at the G2/M
phase. CompuSyn analysis revealed an additive effect of
the two agents on the cell cycle arrest.
Cell cytotoxicity of ribavirin and IFN-α in the human
embryonic kidney cell line (HEK-293)
To examine cytotoxicity of ribavirin and IFN-α in a nor-
mal cell line, the HEK-293 cells were co-treated with these
two agents. The cytotoxicity was then examined using the
MTT assay. After 72-h incubation, the proliferation of
Figure 1 The effect of IFN-α and ribavirin alone and combined IFN-α and ribavirin treatment on the proliferation of the murine and
human RCC cells. (A) Suppression of proliferation induced by IFN-α alone or in combination with ribavirin. (B) Suppression of proliferation
induced by ribavirin alone or in combination with IFN-α. C1: combination of 500 IU/ml of IFN-α and 500 μM ribavirin. C2: 1000 IU/ml of IFN-α
and 1000 μM ribavirin. The suppression was significant in the range of 20–1000 IU/ml of IFN-α or 100–1000 μM ribavirin. (*indicates a significant
difference in comparison with controls).
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bined treatment with different concentrations of riba-
virin and IFN-α. The results, shown in the Figure 4,
demonstrated that this treatment did not have signifi-
cant cytotoxic effect in the normal kidney cell line.
The effect of IFN-α alone, ribavirin alone, or a
combination of IFN-α and ribavirin on RCC cell migration
The transwell assay showed a significant decrease in cell
migration for the cells incubated with IFN-α in compari-
son with untreated cells, for both Renca and 786–0 cell
lines. This effect was concentration-dependent for both
cell lines (p < 0.05) (Figure 5A and B). The treatment
with ribavirin significantly inhibited cell migration in
both cell lines in a similar manner (p < 0.05) (Figure 5C
and D), but the effect of ribavirin on cell migration was
weaker than that of IFN-α. Surprisingly, after combined
IFN-α and ribavirin treatment, fewer cells (50–70) under-
went migration (p < 0.05) (Figure 5E-G). The results
showed that both agents exerted a potent effect on cell
migration. However, in comparison with the results for
the combined treatment with 500 μM of ribavirin and
500 IU/ml of IFN-α, increasing IFN-α concentrationFigure 2 Apoptosis in human and murine RCC cells after treatment w
ribavirin. (A) Apoptosis induced by IFN-α alone. (B) Apoptosis induced by
and ribavirin.caused no further decrease in the number of migrating
cells (in both cell lines, p > 0.05).
The effect of IFN-α alone, ribavirin alone, or combined
treatment on IL-10 and TGF-β secretion in supernatant of
RCC cells
IL-10 concentrations in supernatants of Renca and 786–
0 cells treated with ribavirin at different concentrations
were significantly lower (p < 0.05) than in the superna-
tants from untreated cultures. These results demonstrate
that ribavirin can inhibit IL-10 secretion in RCC cells in
a concentration-dependent manner (Figure 6A). Simi-
larly, IFN-α decreases IL-10 secretion in both treated
RCC cell lines. However, the treatment with a combin-
ation of IFN-α and ribavirin at higher concentration
levels did not inhibit IL-10 secretion more than single-
agent treatments (Figure 6A and B). In contrast, there
was a trend towards increased TGF-β production. When
TGF-β levels were measured with ELISA, we observed
that both IFN-α and ribavirin on their own significantly
increased TGF-β production in a concentration-dependent
manner (in both Renca and 786–0 cells, p < 0.05). The
combined treatment did not significantly increase TGF-βith IFN-α alone, ribavirin alone, or combination of IFN-α and
ribavirin alone. (C) Apoptosis induced by combination of IFN-α
Figure 3 Combined treatment with ribavirin and IFN-α affected the RCC cell cycle. (A) Combination of 500 IU/ml of IFN-α and 500 μM
ribavirin blocked the G2/M phase cell cycle transition of 786–0 cells, in comparison with untreated control 786–0 cells. The percentage of 786–0
cells in the G0/G1 phase increased significantly to 58.32% but the percentage of cells in the G2/M phase decreased to 13.95%. (B) Quantitative
analysis of the cell cycle distribution of 786–0 cells treated with ribavirin alone, IFN-α alone, or a combination of ribavirin and IFN-α (* < 0.05 versus
control group).
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duction caused by IFN-α or ribavirin was more substantial
in 786–0 cells than that in Renca cells (Figure 6C and D).
Discussion
The aim of this study was to evaluate the direct effect of
ribavirin on RCC cells and the possibility that this agent
might become a new candidate for RCC therapy. Ribavi-
rin is a classic anti-viral agent and has been used for the
treatment of various viral diseases for a long time. Previous
studies have demonstrated that IFN-α alone or in combin-
ation with other agents can directly inhibit the growth
of cancer cells. However, up to now, ribavirin has not
been used to treat RCC [11,12]. Our in vitro experiments
revealed that ribavirin could directly inhibit proliferationFigure 4 Combination of ribavirin and IFN-α does not cause significantand migration of murine and human RCC cells, enhance
their apoptosis, and arrest cell cycle progression at the
G2/M phase. The effect of ribavirin on RCC cells was
concentration-dependent. Our results also showed that
ribavirin inhibited IL-10 production and increased TGF-β
secretion. More importantly, combined treatment with
IFN-α and ribavirin had an additive effect on the prolifera-
tion, migration, and induction of apoptosis. In this study,
we did not observe significant toxic effects on normal
cells. Thus, our results suggest that ribavirin might be a
novel agent for the treatment of RCC.
The direct anti-tumor effect of ribavirin cells certainly
deserves further investigation. Increasing ribavirin con-
centration significantly increased the efficacy of its anti-
cancer properties in vitro. We found that ribavirin (atcell toxicity in HEK-293 cells, in comparison with untreated cells.
Figure 5 (See legend on next page.)
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Figure 5 Ribavirin alone, IFN-α alone, or a combination of IFN-α and ribavirin inhibit migration of Renca or 786–0 cells. (A) The effect of
IFN-α on migration of Renca cells (A) and 786–0 cells (B); The effect of ribavirin on migration of Renca cells (C) and 786–0 cells (D); (E) The effect
of combined IFN-α and ribavirin treatment on migration of Renca and 786–0 cells (*indicates a significant difference in comparison with controls).
(F, G) Representative images of crystal violet-stained control and treated Renca and 786–0 cells (combined treatment with IFN-α and ribavirin at
different concentrations).
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inhibited proliferation, induced apoptosis, and inhibited
cell migration. The level of transporter expression in RCC
cells and intracellular levels of ribavirin and its metabolites
are likely to be interrelated. It has been suggested that ri-
bavirin is taken up by nitrobenzylthioinosine-sensitive
(es)-nucleoside transporters and that the concentrative
nucleoside transporters and sodium co-transport could be
important at low ribavirin concentrations [13,14]. High
intracellular levels of ribavirin and its metabolites also de-
pend on the levels of ribavirin in the extracellular media
[15,16]. Detailed studies of ribavirin metabolism and its
transport processes in the RCC cells, which might modu-
late intracellular levels of ribavirin, will be important for
understanding the exact mechanisms of its action.
Ribavirin may be a pivotal combination partner in en-
hancing the efficacy of IFN-α-based therapy. Here, we
demonstrated the additive anti-tumor effect of ribavirin
in combination with IFN-α. A study of an anti-viral therapy
has concluded that ribavirin enhances specific interferon-
sensitive gene expression by amplifying the IFN-α JAK/
STAT pathway; it has shown that STAT1 and STAT3Figure 6 IFN-α alone, ribavirin alone, or a combination of IFN-α and r
Renca and 786–0 cells. (A) IL-10 levels after treatment with ribavirin (100–
after treatment with IFN-α (20–1000 IU/ml) or a combination of IFN-α and rib
a combination of IFN-α and ribavirin. (D) Levels of TGF-β after treatment w
combination of 500 IU/ml of IFN-α and 500 μM ribavirin. C2: 1000 IU/ml o
the range of 20–1000 IU/ml of IFN-α or in the range of 100–1000 μM ribavphosphorylation is higher in hepatocytes co-treated with
ribavirin and IFN-α than after treatment with IFN-α
alone [17]. Another possible mechanism is that ribavirin
stimulates ERK1/2 and subsequently promotes p53 ac-
tivity [18]. In addition, ribavirin upregulates the expres-
sion of IFN-a receptor in hepatocytes and augments
interferon-stimulated gene induction [19,20]. These
mechanisms are at least partly supported by the results
of our study. However, further investigation should be
performed to understand the mechanisms by which the
combination of ribavirin and IFN-α exerts a potent anti-
tumor effect.
It has been reported that ribavirin has anti-tumor
properties in different types of malignant tumors, such
as head and neck squamous cell carcinoma (HNSCC)
cell line FaDu, in breast cancer and AML patients
[15,20,21]. In our study, we demonstrated for the first
time that both murine and human RCC cell lines can re-
spond to the treatment with ribavirin alone or a com-
bination of ribavirin and IFN-α. These results are
consistent with previously reported data. As an onco-
gene, eukaryotic translation-initiation factor 4E (eIF4E)ibavirin inhibit IL-10 production, but increase TGF-β secretion in
1000 μM) or a combination of IFN-α and ribavirin. (B) Levels of IL-10
avirin. (C) Levels of TGF-β after treatment with ribavirin (100–1000 μM) or
ith IFN-α (20–1000 IU/ml) or a combination of IFN-α and ribavirin. C1:
f IFN-α and 1000 μM ribavirin. The suppression was significant within
irin (*indicates a significant difference in comparison with controls).
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which is an element of the mammalian target of rapamy-
cin (mTOR) pathway, has been considered an important
target for ribavirin anti-tumor activity [21,23]. Thus, the
direct effect of ribavirin on RCC cells might be associated
with eIF4E. Ribavirin might also enhance the efficacy of
rapamycin analogues everolimus and temsirolimus in the
treatment of renal cell carcinoma.
Apart from a direct effect on RCC cells, our study also
confirmed that ribavirin reduced IL-10 production and
increased TGF-β secretion, thus exerting an immuno-
modulatory effect in RCC-cell microenvironment. Our
previous studies have indicated that IL-10, a negatively
immunomodulatory cytokine, had the ability to expand
regulatory T cells (Tregs) and induce their conversion
[24,25]. However, a recent clinical study has demon-
strated that high TGF-β1 mRNA levels in peripheral
blood in metastatic RCC patients are independently asso-
ciated with favorable progression-free survival and overall
survival. Thus, unlike IL-10, TGF-β appears to have an
immune-promoting function [26]. More importantly, riba-
virin has immunostimulatory effect (by multiple mechan-
ism) in hepatitis C, such as enhancing proliferation of T
effector cells, increasing production of IFN-Ɣ in Th1 cells,
and reversing Treg-mediated suppression of T effector
cells [4]. It has been also suggested that ribavirin might
reverse immunosuppression in malignant tumors, par-
ticularly in RCC. All these data, in conjunction with our
results, suggest that ribavirin alone or in combination
with other agents might be useful in immunotherapy for
RCC.
Conclusions
Our study provides the evidence that ribavirin in com-
bination with IFN-α can significantly inhibit the prolifer-
ation and migration, induce apoptosis, arrest the cell
cycle at the G2/M phase, and decrease IL-10 production
in the RCC cell lines. Moreover, this treatment has no
toxic effects in normal cell line. We still need to conduct
further investigation of the precise mechanism by which
ribavirin directly suppresses RCC cells. Anti-tumor ef-
fects of ribavirin should also be carefully examined in a
model of RCC. These are some of the aspects of this
complex system currently studied in our laboratory.
Materials and methods
Cell line and cell culture
The study was approved by the Ethics Committee of
Harbin Medical University (13016). This study used hu-
man RCC cell lines 786–0 cells, which were donated by
Dr. Shen of the Department of Urology at The first affili-
ated hospital of Jilin University. Mice renal carcinoma
cell lines Renca and HEK-293 cells purchased from
American Type Culture Collection. Culture medium forRenca consisted of complete growth medium RPMI-1640
(Hyclone, Irvine, CA, USA) supplemented with heat-
inactivated (56°C, 30 min) 10% fetal bovine serum (FBS,
Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin
(Gibco). 786–0 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM, Hyclone) containing 10% FBS
(Hyclone) and 100 U/ml penicillin and 100 μg/ml strepto-
mycin (Gibco). Above cells were cultured in an atmos-
phere of 5% CO2 in air at 37°C.
Ribavirin and interferon α. Ribavirin and recombin-
ant mouse and human Interferon α (IFN-α) were pur-
chased Tokyo Chemical Industry (TCI) and eBioscience,
respectively.
Effect of ribavirin alone, IFN-α alone or combination of
ribavirin and interferon α on proliferation of renca and
786–0 cell lines
All cells were plated on 96-wells plates (5 × 103 cells/well)
incubated in respectively serum overnight at 37°C in a 5%
CO2 incubator. After removal of media, 100 μl/well
media containing different concentration of agents (ri-
bavirin alone, IFN-α alone and combination of ribavirin
and IFN-α) were added to each well. Plates were incu-
bated for 72 h without subsequent media changed. There-
after cells proliferation was measured using Cell Counting
kit (CCK-8, Dojindo, Japan). Absorbance was measured at
450 nm. The OD values were measured to represent pro-
liferation of cells. All the experiments were performed in
triplicate.
Assessment apotosis by annexin-V and propidium iodide
To evaluate effect of ribavirin alone, IFN-α alone or
combination ribavirin and interferon α on renal cell
carcinoma cells, annexin-V and propidium iodide (PI)
(Apoptosis Detection Kit, annexin-V-FITC, BD, Biosci-
ences Pharmingen, San Diego, CA) were used double
stain technique, which was also used to distinguish be-
tween apoptosis (annexin-V positive, PI negative) and
necrotic (annexin-V positive, PI positive) cells. 2 × 105
cells under different culture condition were resuspended
in 100 μl binding buffer, incubated with 2 μl Annexin-V-
FITC (20 μg/ml) for 15 minutes on the ice in the dark,
thereafter, each sample was incubated with 1 μl PI (50
μg/ml) for 2 minutes, and were then immediately
analyzed by an Accuri C6 flow cytometer (BD Accuri
Cytometers, MI). A minimum of 10,000 events was ac-
quired for each sample.
Cell cycle analysis by flow cytometry
To examine the effect of ribavirin and IFN-α on the renal
cell carcinoma cells, we performed cell cycle analysis using
above flow cytometry following manufacturer’s instruc-
tion. Briefly, the cells treated with ribavirin and IFN-α
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essed for cell cycle analysis.
Cytotoxicity analysis of ribavirin and IFN-α with MTT
assay
HEK-293 cells from American Type Culture Collection
were seeded in 96-well flat bottom tissue culture plates
at a density approximately 0.5-1 × 104/well and were cul-
tured. When the cells paved each bottom of well, the
cells was incubated with or without ribavirin and IFN-α
at different concentrations. After the cells were grown
for 72 h, a volume 10 μl of the MTT reagent (Sigma,
Hamburg, Germany) was added to each well. The plate
was incubated for another 4 h at 37°C. After the MTT
crystals were then solubilized with DMSO, absorbance
of the cells was measured at 490 nm. Cytotoxity was
expressed with OD value. All MTT experiments were
performed in triplicates.
Transwell migration assay
The assay was performed using the 24 well conning
chamber plate with 8-μm pore size polycarbornate mem-
berane filters. 1 × 105/well cells were placed in the upper
chamber containing DMEM with 10% FBS, the lower
chamber also contained DMEM with 10% FBS. The
plates with cells were incubated at 37°C in a 5% CO2 in-
cubator for 48 h. After incubation, the cells on the mem-
berane filter were fixed with 4% (v/v) formaldehyde for
10 minutes at room temperature. The samples were
washed with phosphate buffered solution (PBS) and were
stained with 0.5% crystal violet for 30 minutes. The sam-
ples were then washed (×3) with PBS. The cells on the
upper surface of the filter removed with a cotton swab.
The migratory cells were evaluated by counting the cells
that migrated to the lower side of the filter by bright
field microscopy at 200× magnification. Five random
fields counted for each filter, and each sample was
assayed in triplicate.
Detection of IL-10 and TGF-β concentration in the
supernatant by ELISA
To investigate effect IFN-α alone, ribavirin alone, and
combination of IFN-α and ribavirin on production of IL-
10 and TGF-β in the cell lines, we performed ELISA
assay. The supernatant of each culture condition was
collected. Thereafter all samples were measured using
ELISA kit for IL-10 and TGF-β as per manufacturer’s
instructions.
Statistical analysis
All experiments were repeated multiple and the results
were expressed as the mean ± SD. Statistical analysis
was performed using SSPS 13.0 software. One-way
ANOVA with a multiple comparison was used for dataanalysis. P < 0.05 was considered to be significant. To de-
termine synergistic, additive or antagonistic effect of the
combination of ribavirin and IFN-α, we take the method
of interaction analysis using CompuSyn (ComboSyn,
Inc). We used to calculate the combination index (CI).
Synergy, additivity and antagonism are defined as CI < 1,
CI = 1, CI > 1, respectively.
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